AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $223,304 | -94.7% | 21,680 | -91.6% | 0.00% | -100.0% |
| Q2 2023 | $4,252,664 | +1692.6% | 258,050 | +896.4% | 0.00% | – |
| Q1 2023 | $237,235 | -55.8% | 25,899 | -65.4% | 0.00% | – |
| Q4 2022 | $536,277 | +562.1% | 74,899 | +125.5% | 0.00% | – |
| Q2 2022 | $81,000 | -72.3% | 33,220 | -22.4% | 0.00% | – |
| Q1 2022 | $292,000 | -78.3% | 42,804 | -74.3% | 0.00% | – |
| Q4 2021 | $1,348,000 | +164.3% | 166,869 | +220.9% | 0.00% | – |
| Q3 2021 | $510,000 | +335.9% | 52,000 | +198.9% | 0.00% | – |
| Q2 2021 | $117,000 | -89.3% | 17,397 | -85.6% | 0.00% | – |
| Q1 2021 | $1,094,000 | +835.0% | 121,005 | +589.7% | 0.00% | – |
| Q4 2020 | $117,000 | +23.2% | 17,545 | +50.0% | 0.00% | – |
| Q2 2020 | $95,000 | +66.7% | 11,700 | -15.3% | 0.00% | – |
| Q3 2019 | $57,000 | – | 13,819 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |